The comprehensive details about few active gainers from biotech sector, during the recent trade are illustrated as under:
Enzo Biochem, Inc (NYSE:ENZ) gained 14.79%, and closed to $2.95, during the last trading session, soon after is an integrated life sciences and biotechnology company On February 10, 2015, the company recently declared the development of a new novel platform with consequential and broad application for detection of genotypic and phenotypic markers via flow cytometry, in addition to the first product for its use addressing the cervical cancer testing market. Enzo Clinical Laboratory has presented an application to the New York State Department of Health in advance of offering services based on the FlowScript assay. Upon receiving approval, Enzo will be the first clinical laboratory to provide this assay to physicians and other clinical labs, to which it will also make accessible key reagents for purchase.
Enzo Biochem, Inc (NYSE:ENZ) an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.
STAAR Surgical Company (NASDAQ:STAA) increased 12.85%, and closed to $7.20, during the last trading session, after the following news the company recently declared that it will release its financial results for the fourth quarter ended January 2, 2015 on Wednesday, February 25, 2015 after the market close. STAAR will host a conference call and video webcast on Wednesday, February 25 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to talk about these results and recent corporate developments.
STAAR Surgical Company (NASDAQ:STAA) together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company offers implantable collamer lenses (ICL) comprising Visian ICL to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness
Second Sight Medical Products Inc (NASDAQ:EYES) enhanced 32.08%, and closed to $11.20, during the last trading session, after is a medical device company that recently declared that all three of the centers approved to implant the Argus II Retinal Prosthesis System (“Argus II”) under the French Government national healthcare reimbursement program entitled ‘Forfait Innovation’ have successfully accomplished their first implants in patients with retinitis pigmentosa (RP). Current French implant centers are located in Paris, Bordeaux, and Strasbourg.
Second Sight Medical Products Inc (NASDAQ:EYES) a medical device company, develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients. The company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. It has operations in North America, Europe, and the Middle East.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rose 1.64%, and closed to $202.00, during the last trading session, after formerly Biovail Corporation, is a multinational, specialty pharmaceutical company recently declared the presentation of new long-term, preliminary results from the Phase II STAND trial demonstrating a robust immune response with PROVENGE® (sipuleucel-T) that keeps on two years after concluding treatment in men with biochemically-recurrent prostate cancer (BRPC). The findings, together with valuable data from the ongoing Phase IV registry, PROCEED, related to rising enrollment of African Americans in prostate cancer trials, are being presented at the 2015 Genitourinary Cancers Symposium (ASCO GU) February 26-28 in Orlando, Florida .
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products comprise Solodyn, an oral antibiotic that treats red and pus-filled pimples, in addition to Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution.
BSD Medical Corporation (NASDAQ:BSDM) raised 26.53%, and closed to $0.620, during the last trading session, after, is a life sciences company recently unveiled its new name and corporate identity, Perseon Corporation (Perseon). The Company’s new name is coupled with a new visual identity, counting the new tagline “Science for Humanity.” In conjunction with the corporate name change to Perseon, the ticker symbol for BSD Medical’s ordinary shares traded on The Nasdaq Capital Market will change from “BSDM” to “PRSN,” effective February 25, 2015.
BSD Medical Corporation (NASDAQ:BSDM) develops, manufactures, markets, and services systems to treat cancer and benign diseases using heat therapy delivered through radiofrequency (RF) and microwave energy in the United States and internationally.
